Every medical breakthrough casts a shadow, and ketamine's is longer than most realize. Dr. Ben Synth exposes the concerning rise of "ketamine mills"—profit-driven clinics with minimal oversight and undertrained providers. Explore why thirty to forty percent of patients don't respond to treatment, ketamine's addiction potential, and the stark access inequalities creating two-tiered mental healthcare. From regulatory gray zones to long-term safety unknowns, this episode examines provider training gaps, inappropriate patient selection, and the ethical questions surrounding off-label use. While ketamine represents genuine hope for many, realizing its promise requires confronting risks, limitations, and inequities that threaten vulnerable patients seeking help.https://amzn.to/4hSW7bdThis content was created in partnership and with the help of Artificial Intelligence AI

Ver todos los episodios